论文部分内容阅读
核因子κB(NF-κB)作为真核细胞中广泛存在的转录调节蛋白质因子,它的异常激活或完全抑制与多种疾病的发生有关。在肾脏疾病的发病过程中许多因素可刺激NF-κB活化。国内外研究发现多种药物可通过调节基因易位,促进IκB受体及其配体的活化,增加IκBα水平,活化甲羟戊酸途径及生成NF-κB超抑制物等途径抑制NF-κB表达,从而缓解及治疗肾脏疾病。多种药物联合运用的提出及新型抗NF-κB药物的研究都有助于探索肾脏疾病治疗的新途径。
Nuclear factor kappa B (NF-κB), a ubiquitous transcriptional regulator of protein in eukaryotic cells, is associated with the abnormal activation or complete suppression of various diseases. In the pathogenesis of kidney disease many factors can stimulate NF-κB activation. Domestic and foreign studies have found that a variety of drugs can inhibit the expression of NF-κB by regulating gene translocation, promoting IκB receptor and its ligand activation, increasing IκBα level, activating mevalonate pathway and generating NF-κB superinhibitors , To alleviate and treat kidney disease. Proposed multi-drug combination and new anti-NF-κB drug research will help explore new ways to treat kidney disease.